Tobacco Factory Transformed to Manufacture Five Hallucinogenic Substances

Researchers at the Weizmann Institute of Science have transformed tobacco plants to produce five powerful psychedelic compounds typically derived from other plants and fungi. This innovative approach is argued to be more sustainable and efficient, facilitating the research of therapeutic applications and future medicinal production.

Asaf Aharoni and his team utilized a technique known as agroinfiltration, where bacteria are utilized to introduce genes from various organisms into benthamiana tobacco. Although this method results in temporary production of desired proteins, as the DNA isn’t integrated into the plant’s genome, it serves as a stepping stone in biotechnology.

By introducing nine specific genes, the modified plants are capable of producing psilocin and psilocybin, compounds found in certain mushrooms, alongside DMT, bufotenine, and 5-methoxy-DMT, which are derived from plants and Colorado River toads (Incilius Alvarius).

Though permanent genetic modifications could be devised for these plants, Aharoni notes the complications due to the recreational nature of the generated compounds: “It’s challenging to inherit the traits, yet demand for seed may arise.” Similar methods had been applied to tomatoes, potatoes, and corn.

The medical landscape for psychedelic compounds is gradually evolving. Aharoni highlights that while harvesting these substances from nature poses a risk of depleting habitats, the cultivation of tobacco in controlled environments would mitigate this concern and streamline production for research.

The strategy of “pharmaceutical agriculture” isn’t a novel concept. The United States approved plant-derived protein medicines in 2012, and by 2002, corn was engineered to produce pharmaceutical proteins. Noteworthy, a 2022 study revealed that tobacco can also synthesize cocaine, yielding about 400 nanograms per milligram of dried leaves—substantially lower than coca plants.

According to researchers like Rupert Frey, approximately 25% of prescription medications are derived from plants, highlighting the potential for “green factories” where new compounds are cultivated in greenhouses. Frey asserts, “Understanding how to create these compounds is vital, demonstrating the capabilities of a tobacco-based system.”